Diamyd receives new approval for study to follow Swedish children and confirm long-term effect of the Diamyd® diabetes vaccine

Diamyd Medical has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company’s Phase II study of the Diamyd® diabetes vaccine, which started four years ago. The aim of the follow-up study is to confirm the vaccine’s long-term effect.“Clinical studies with Diamyd® have demonstrated significant efficacy in preserving the body’s own ability to produce insulin,” says Elisabeth Lindner, President and CEO of Diamyd Medical. “We will now, in parallel with our ongoing large international Phase III trials, establish that the